clinical trial · NCT04803006
A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PANORAMA)
Kidney TransplantationTCD601
brief summary
The purpose of this study is to determine the optimal regimen for the use of siplizumab, a human anti-CD2 antibody, combined with donor bone marrow cells and non-myeloablative conditioning, for tolerance induction in living donor renal transplantation
started
Jan 17, 2023
primary completion
Oct 30, 2025
completion
Oct 30, 2025
last updated
Feb 6, 2026
official title
An Adaptive, Regimen Finding, Safety and Tolerability Study of TCD601 (Siplizumab), a Human Anti-CD2 Antibody, Combined With Donor Bone Marrow Cell Infusion and Non-myeloablative Conditioning, for Tolerance Induction in Living Donor Renal Transplantation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol